European Journal of Cancer最新文献

{"title":"Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study","authors":"Kazumasa Yamamoto ,&nbsp;Hideaki Bando ,&nbsp;Toshihiro Misumi ,&nbsp;Tomomi Nishikawa ,&nbsp;Masashi Wakabayashi ,&nbsp;Kentaro Yamazaki ,&nbsp;Yoshihiko Maehara ,&nbsp;Eiji Oki ,&nbsp;Leonard B. Saltz ,&nbsp;Jean-Yves Douillard ,&nbsp;Cornelis JA Punt ,&nbsp;Miriam Koopman ,&nbsp;Eric Van Cutsem ,&nbsp;Carsten Bokemeyer ,&nbsp;Alan P. Venook ,&nbsp;Volker Heinemann ,&nbsp;Chiara Cremolini ,&nbsp;J. Randolph Hecht ,&nbsp;Hans-Joachim Schmoll ,&nbsp;Goro Nakayama ,&nbsp;Takayuki Yoshino","doi":"10.1016/j.ejca.2025.116034","DOIUrl":"10.1016/j.ejca.2025.116034","url":null,"abstract":"<div><h3>Introduction</h3><div>The combination of oxaliplatin-based doublet chemotherapy and molecular targeted agents is the standard first-line treatment for metastatic colorectal cancer. However, the temporal evolution of associated treatment outcomes is unclear. We utilized Aide et Recherche en Cancérologie Digestive (ARCAD) data to evaluate the chronological changes in clinical outcomes associated with this regimen in metastatic colorectal cancer.</div></div><div><h3>Methods</h3><div>An individual patient data meta-analysis was performed using data from 5424 patients enrolled in 13 randomized controlled trials within the ARCAD database between 2004 and 2017. Eligible patients received oxaliplatin-based chemotherapy combined with bevacizumab or anti-epidermal growth factor receptor antibodies. Intervals of 2004–2008, 2009–2013, and 2014–2017 were examined. Overall, progression-free, and post-progression survivals were analyzed using Kaplan–Meier and Cox proportional hazards models adjusted for key prognostic factors.</div></div><div><h3>Results</h3><div>Median overall survival improved over time, from 21.4 months (2004–2008) to 28.6 months (2009–2013) and 29.7 months (2014–2017). Similar trends were observed for progression-free and post-progression survivals. Multivariable analysis confirmed the treatment period as an independent prognostic factor for overall and progression-free survivals. Subgroup analyses revealed improvements in overall survival for left-sided and <em>RAS</em> wild-type tumors, whereas minimal gains were found for right-sided or <em>RAS</em>-mutated tumors. Increased use of subsequent therapies contributed to prolonged post-progression survival.</div></div><div><h3>Conclusions</h3><div>We demonstrated progressive improvements in survival outcomes for patients with metastatic colorectal cancer receiving first-line oxaliplatin-based chemotherapy plus molecular targeted agents. The findings highlight the importance of biomarker-driven treatment strategies and the evolving role of subsequent therapies in optimizing clinical outcomes.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"230 ","pages":"Article 116034"},"PeriodicalIF":7.1,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145243950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence of published randomised Phase 3 cancer trials to principles proposed by common-sense oncology","authors":"Omar Abdihamid ,&nbsp;Bishal Gyawali ,&nbsp;Christopher M. Booth ,&nbsp;Elizabeth A. Eisenhauer ,&nbsp;Wilma M. Hopman ,&nbsp;Brian Shkabari ,&nbsp;Dario Trapani ,&nbsp;Haydee C. Verduzco-Aguirre ,&nbsp;Brooke E. Wilson ,&nbsp;Ian F. Tannock","doi":"10.1016/j.ejca.2025.116041","DOIUrl":"10.1016/j.ejca.2025.116041","url":null,"abstract":"<div><h3>Background</h3><div>Randomised Controlled Trials (RCTs) should be designed rigorously, analysed appropriately, and reported accurately to enable shared decision making about cancer treatments that is aligned with patient priorities. Common-Sense Oncology (CSO) has published principles for their design, analysis, and reporting, with checklists to help ensure this.</div></div><div><h3>Methods</h3><div>We applied CSO checklists to 55 RCTs evaluating systemic therapies for solid tumours published in 2023 to assess the extent to which they adhered to CSO principles, and to provide a benchmark for comparison with future trials.</div></div><div><h3>Results</h3><div>Progression-free survival (PFS) and overall survival (OS) were primary endpoints in 53 % and 43 % of 47 trials for advanced disease, respectively. Twelve of 55 (22 %) trials had a control arm judged to be an inappropriate standard of care at time of trial initiation, 60 % justified their selection of an alternative primary endpoint to OS, and 42 % included Health-Related Quality-of-Life (HRQoL) measures as a secondary endpoint. Only two (3.6 %) trials addressed strategies to limit censoring and dropout: numbers of censored patients were shown below Kaplan-Meier curves in 40 % of the trials, but sensitivity analysis to determine potential effects of censoring was undertaken in only 5 (9 %) trials. Persistent toxicities were reported in only one trial, and only 3 trial reports mentioned cost or cost-effectiveness.</div></div><div><h3>Conclusions</h3><div>By applying the CSO checklists systematically, we identified several deficiencies in the design, analysis, and reporting of RCTs evaluating systemic therapies for solid cancers. Our survey highlights the need for improvements in design and reporting of RCTs to enable readers to correctly interpret their results.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"230 ","pages":"Article 116041"},"PeriodicalIF":7.1,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145218129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS)","authors":"Ilias Houda ,&nbsp;Dwayne Naves ,&nbsp;Ezgi B. Ulas ,&nbsp;Birgit I. Lissenberg-Witte ,&nbsp;Nicole P. Barlo ,&nbsp;Elisabeth A. Kastelijn ,&nbsp;Hicham Bouhaddou ,&nbsp;Rimsha Shaikh ,&nbsp;Chris Dickhoff ,&nbsp;Teodora Radonic ,&nbsp;Famke L. Schneiders ,&nbsp;Suresh Senan ,&nbsp;Ronald A.M. Damhuis ,&nbsp;Idris Bahce","doi":"10.1016/j.ejca.2025.116042","DOIUrl":"10.1016/j.ejca.2025.116042","url":null,"abstract":"<div><h3>Background</h3><div>Guidelines recommend cisplatin as the preferred platinum agent in the first-line treatment for small cell lung cancer (SCLC), especially limited-stage disease (LS-SCLC). However, during the COVID-19 pandemic, carboplatin use likely increased due to logistical advantages. We evaluated the pandemic’s impact on platinum agent utilization in the Netherlands and compared overall survival (OS) and safety between cisplatin and carboplatin.</div></div><div><h3>Methods</h3><div>Using Netherlands Cancer Registry data, first-line platinum-based treatments for LS-SCLC and extensive-stage SCLC (ES-SCLC) between 2018 and 2023 were analyzed. OS was evaluated using univariable and multivariable analyses. Grades 3–5 treatment-related adverse events were studied in three hospitals.</div></div><div><h3>Findings</h3><div>Overall, 1683 LS-SCLC (carboplatin, <em>N</em> = 1011[60 %]; cisplatin, <em>N</em> = 672[40 %]) and 3668 ES-SCLC (carboplatin, <em>N</em> = 3002[82 %]; cisplatin, <em>N</em> = 666[18 %]) patients were included. During the pandemic, quarterly usage rates of carboplatin reached up to 81 % and 90 % in LS-SCLC and ES-SCLC, respectively. In LS-SCLC, univariable analysis showed significantly shorter median OS with carboplatin compared to cisplatin (17.9m <em>vs</em>. 26.3m; HR, 1.48; 95 %CI, 1.31–1.68; <em>p</em> &lt; 0.001). Similar findings were observed in ES-SCLC (8.0m <em>vs</em>. 9.3m; HR, 1.19; 95 %CI, 1.09–1.30; <em>p</em> &lt; 0.001). However, multivariable analyses, after adjusting for confounders, showed no significant OS differences in either LS-SCLC (HR, 1.06; 95 %CI, 0.90–1.25; <em>p</em> = 0.463) or ES-SCLC (HR, 1.01; 95 %CI, 0.92–1.12; <em>p</em> = 0.785). Confounders were performance status (PS), age, sex, and chemoradiotherapy type for LS-SCLC, and PS, age, sex, stage, and liver metastases for ES-SCLC. Hematologic toxicity was higher with carboplatin, while cisplatin led to more nonhematologic toxicity.</div></div><div><h3>Interpretation</h3><div>These findings challenge the long-standing belief of cisplatin’s superiority and support the adoption of carboplatin in SCLC.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"230 ","pages":"Article 116042"},"PeriodicalIF":7.1,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcellular immune interactions reveal a MHC class I related mechanism of immune evasion in cutaneous T-cell lymphoma","authors":"Pacome Prompsy,&nbsp;Christoph Iselin,&nbsp;Yun-Tsan Chang,&nbsp;Yi-Chien Tsai,&nbsp;Chella Krishna Vadivel,&nbsp;Gabriele Roccuzzo,&nbsp;Pauline Bernard,&nbsp;Gabriela Blanchard,&nbsp;Maël Blanchard,&nbsp;Constanze Jonak,&nbsp;Mitchell P. Levesque,&nbsp;Patrick Brunner,&nbsp;Rupert Langer,&nbsp;Steve Pascolo,&nbsp;Denis Schapiro,&nbsp;Michel Gilliet,&nbsp;Wolfram Hoetzenecker,&nbsp;Terkild B. Buus,&nbsp;Niels Ødum,&nbsp;Emmanuella Guenova","doi":"10.1016/j.ejca.2025.115823","DOIUrl":"10.1016/j.ejca.2025.115823","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":""},"PeriodicalIF":7.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145289535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pro tumorigenic role of lower dermal fibroblasts and fibroblast-derived ECM in early mycosis fungoides","authors":"Lilach Moyal,&nbsp;Noam Abraham,&nbsp;Anna Aronovich,&nbsp;Batia Gorovitz,&nbsp;Emmilia Hodak","doi":"10.1016/j.ejca.2025.115810","DOIUrl":"10.1016/j.ejca.2025.115810","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":""},"PeriodicalIF":7.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145289644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct molecular signatures predict early mortality in advanced mycosis fungoides","authors":"Marcos Rebollo-González,&nbsp;Marta Rodríguez,&nbsp;Carlos Morenoíchez,&nbsp;Juan Torre-Castro,&nbsp;Marıá Moreno-Delgado,&nbsp;Alfonso Gotor-Rivera,&nbsp;Fina Climent,&nbsp;Cristina Muniesa,&nbsp;Octavio Servitje,&nbsp;Francisco Javier Dıáz de la Pinta,&nbsp;Pablo L. Ortiz Romero,&nbsp;José Luis Rodríguez Peralto,&nbsp;Rebeca Manso,&nbsp;Socorro Marıá Rodríguez Pinilla","doi":"10.1016/j.ejca.2025.115812","DOIUrl":"10.1016/j.ejca.2025.115812","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":""},"PeriodicalIF":7.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145289646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Observing the cancer microenvironment in mycosis fungoides following immune checkpoint blockade","authors":"Duncan Murray,&nbsp;Samantha Drennan,&nbsp;James Van De Hear,&nbsp;Suzy Eldershaw,&nbsp;Jammbe Musoro,&nbsp;Jose Casas-martin,&nbsp;Hayden Pearce,&nbsp;Pablo Ortiz,&nbsp;Martine Bagot,&nbsp;Pietro Quaglino,&nbsp;Emmanuella Guenova,&nbsp;Constanze Jonak,&nbsp;Evangelia Papadavid,&nbsp;Rene Strazenback,&nbsp;Delphine Satori,&nbsp;Sandrine Marreaud,&nbsp;Maxime Battistella,&nbsp;Rein Willemze,&nbsp;Rudolf Stadler,&nbsp;Robert Knobler,&nbsp;Paul Moss","doi":"10.1016/j.ejca.2025.115814","DOIUrl":"10.1016/j.ejca.2025.115814","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":""},"PeriodicalIF":7.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145289648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of tumor clone frequency in mycosis fungoides and Sézary syndrome","authors":"Madeline Williams BS,&nbsp;Laura Gleason MD,&nbsp;Neda Nikbakht MD, PhD","doi":"10.1016/j.ejca.2025.115859","DOIUrl":"10.1016/j.ejca.2025.115859","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":""},"PeriodicalIF":7.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145289655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone marrow biopsy in cutaneous T-Cell Lymphoma: A multispecialty survey exposes divergence between evidence and practice","authors":"Elle Kim MHS,&nbsp;Victoria Slavinsky MS,&nbsp;Sarem Rashid BS,&nbsp;Gayane Yenokyan MD, PhD,&nbsp;Alejandro Gru MD,&nbsp;Francine Foss MD,&nbsp;Sima Rozati MD, PhD","doi":"10.1016/j.ejca.2025.115867","DOIUrl":"10.1016/j.ejca.2025.115867","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":""},"PeriodicalIF":7.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145289663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and clinical characteristics of coexisting autoimmune connective tissue disease and cutaneous T-cell lymphoma in a global dataset of deidentified electronic health records","authors":"Jeffrey D. Weiner,&nbsp;Apurva Dev,&nbsp;Saloni Patel,&nbsp;Jun Kang,&nbsp;Sima Rozati","doi":"10.1016/j.ejca.2025.115868","DOIUrl":"10.1016/j.ejca.2025.115868","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":""},"PeriodicalIF":7.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145289664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}